Bristol-Myers says FDA places partial hold on Opdivo myeloma trials
September 06, 2017 at 18:17 PM EDT
Sept 6 (Reuters) - The U.S. Food and Drug Administration has placed a partial hold on three clinical trials testing Bristol-Myers Squibb's immunotherapy Opdivo in combination with other medicines for multiple myeloma due to risks seen in similar studies involving a rival drug, the company said on Wednesday.